The identification of mutations in certain genes, such as the fms-related tyrosine kinase 3 (FLT3), CCAAT/enhancer binding protein alfa (C/EBPα), runt-related transcription factor 1 (RUNX1), myeloid-lymphoid or mixed lineage leukemia (MLL), Wilms tumor (WT1) and nucleophosmin (NPM) 1 genes, in acute myeloid leukemia (AML) has significantly improved our understanding of leukemogenesis [1-4]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.